Cancer drug combo trial ends early – little known

NCT ID NCT04986852

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial tested a combination of two drugs, olinvacimab and pembrolizumab, in 19 women with metastatic triple-negative breast cancer. The goal was to see if the combination could shrink tumors. However, the study was terminated early, so we have limited information on how well it worked or its safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

olinvacimab and pembrolizumab

What this could lead to

If it worked, this combination could have offered a new treatment option for metastatic triple-negative breast cancer.

What could go wrong

The trial was terminated early with only 19 participants, so we have very little data. It is unclear if the combination is effective or safe.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC TRIPLE-NEGATIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hollywood Private Hospital

    Nedlands, Western Australia, 6009, Australia